

Practical Nuclear Medicine

Edited by

Peter F Sharp
Howard G Gemmell

*Department of Biomedical Physics and Bioengineering,
University of Aberdeen and Aberdeen Royal Hospital NHS Trust,
Aberdeen*

and

Francis W Smith

*Department of Nuclear Medicine,
Aberdeen Royal Hospitals NHS Trust,
Aberdeen*

Oxford New York Tokyo
OXFORD UNIVERSITY PRESS

1998

Oxford University Press, Great Clarendon Street, Oxford OX2 6DP

Oxford New York

Athens Auckland Bangkok Bogota Bombay

Buenos Aires Calcutta Cape Town Dar es Salaam

Delhi Florence Hong Kong Istanbul Karachi

Kuala Lumpur Madras Madrid Melbourne

Mexico City Nairobi Paris Singapore

Taipei Tokyo Toronto Warsaw

and associated companies in

Berlin Ibadan

Oxford is a trade mark of Oxford University Press

Published in the United States

by Oxford University Press Inc., New York

© Oxford University Press, 1998

All rights reserved. No part of this publication may be reproduction, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press. Within the UK, exceptions are allowed in respect of any fair dealing for the purpose of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, or in the case of reprographic reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms and in other countries should be sent to the Rights Department, Oxford University Press, at the address above.

This book is sold subject to the condition that it shall not, by way of trade or otherwise, be lent, re-sold, hired out, or otherwise circulated without the publisher's prior consent in any form of binding or cover other than that in which it is published and without a similar condition including this condition being imposed on the subsequent purchaser.

A catalogue record for this book is available from the British Library

Library of Congress Cataloging in Publication Data

Practical nuclear medicine / edited by Peter F. Sharp, Howard G. Gemmell, and Francis W. Smith. — 2nd ed.

(Oxford medical publications)

Includes bibliographical references.

I. Nuclear medicine. I. Sharp, Peter F. II. Gemmell, H. G.

III. Smith, F. W. (Francis W.) IV. Series.

[DNLN: 1. Nuclear Medicine. WN 440 P895 1998]

R895.P73 1998 616.07'575—dc21 97-34661

ISBN 0 19 262842 9 (hbk)

0 19 262841 0 (pbk)

Typeset by

EXPO Holdings, Malaysia

Printed in Great Britain by

The Bath Press

OXFORD MEDICAL PUBLICATIONS

Practical Nuclear Medicine

Second Edition

Preface to the second edition

Since the first edition of this book was published, the face of medical diagnostic imaging has continued to develop. MRI continues to find new applications, most notably, so far as nuclear medicine is concerned, in the development of functional imaging. The application of X-rays has also moved forward, with the continued development of digital systems, once the prerogative of nuclear medicine, and spiral CT.

Nuclear medicine itself has also moved forward. No self-respecting nuclear medicine department will now wish to be seen without a dual-headed camera and even triple-headed cameras are to be found in some departments. The dual headed camera offers real advantages for bone imaging and SPECT. Analogue position circuitry in gamma cameras, which has changed little since Anger's day, is now being supplanted by fully digital approaches, offering the advantage of greater reliability and the ability to handle higher count-rates. The holy grail of accurate quantitation from SPECT has been brought closer with the introduction of transmission imaging. In the field of radiopharmaceuticals ^{99m}Tc labelled myocardial perfusion agents are well established; one of them, MIBI, has been used in other areas such as parathyroid imaging. ^{99m}Tc HMPAO is now widely used, not only for brain blood flow imaging but also for white cell labelling in order to image infection. Nuclear medicine's role in oncology is increasing, for example in the application of ^{123}I MIBG and ^{111}In Octreotide.

The success of the first edition has shown that there was a need for the practical manual format of the book and this has been maintained in the second edition. Nothing is perfect, however, and changes have been introduced. The techniques of nuclear medicine are wider than imaging. A chapter has now been included specifically dealing with non-imaging. Recently one of the areas being strongly promoted by manufacturers has been the potential use of dual-headed cameras for positron emission tomography (PET). In conjunction with central radionuclide production facilities this offers the opportunity for a wider clinical use of the longer-lived PET radiopharmaceuticals, in particular ^{18}F fluorodeoxyglucose. A chapter on PET imaging has therefore been introduced.

A surprisingly large number of the original authors have been prepared to revise their contributions; to them we are, once again, very grateful. We would also like to warmly thank the new contributors. Link Medical and Amersham International kindly provided financial help towards the cost of the colour plates. Once again we would like to acknowledge the support of our colleagues and of our long-suffering families.

Aberdeen
October 1997

P.F.S
H.G.G
F.W.S

Contributors

- R W Barber** Nuclear Medicine Department, Addenbrooke's NHS Trust, Cambridge
P P Dendy Department of Medical Physics, Addenbrooke's NHS Trust, Cambridge
J Doherty Pharmacy Department, Aberdeen Royal Hospitals NHS Trust, Aberdeen
A T Elliott Department of Clinical Physics, University of Glasgow, Glasgow
H G Gemmell Department of Biomedical Physics and Bioengineering, University of Aberdeen and Aberdeen Royal Hospitals NHS Trust, Aberdeen
K E Goldstone East Anglian Regional Radiation Protection Services, Addenbrooke's NHS Trust, Cambridge
D Graham Pharmacy Department, Aberdeen Royal Hospitals NHS Trust, Aberdeen
H W Gray Department of Nuclear Medicine, Glasgow Royal Infirmary University NHS Trust, Glasgow
M D Gross Nuclear Medicine and Magnetic Resonance Imaging School of Medicine, Vanderbilt University, Nashville, USA
L K Harding Department of Physics and Nuclear Medicine, City Hospital NHS Trust, Birmingham
T E Hilditch Department of Clinical Physics, University of Glasgow, Glasgow
W H Martin Nuclear Medicine and Magnetic Resonance Imaging School of Medicine, Vanderbilt University, Nashville, USA
G W Middleton Department of Medical Physics and Bioengineering, University of Wales, Cardiff
A Notghi Department of Physics and Nuclear Medicine, City Hospital NHS Trust, Birmingham
A M Peters Department of Imaging, Royal Postgraduate Medical School, Hammersmith Hospital, London
A C Perkins Medical Physics Department, Queen's Medical Centre, University Hospital, Nottingham
M P Sandler Nuclear Medicine and Magnetic Resonance Imaging, School of Medicine, Vanderbilt University, Nashville, USA
B Shapiro Nuclear Medicine and Magnetic Resonance Imaging, School of Medicine, Vanderbilt University, Nashville, USA
P F Sharp Department of Biomedical Physics and Bioengineering, University of Aberdeen and Aberdeen Royal Hospital NHS Trust, Aberdeen
F W Smith Department of Nuclear Medicine, Aberdeen Royal Hospitals NHS Trust, Aberdeen, AB9 2ZD, UK
R T Staff Department of Biomedical Physics and Bioengineering, University of Aberdeen and Aberdeen Royal Hospitals NHS Trust, Aberdeen
S Walton Cardiology Department, Aberdeen Royal Hospitals NHS Trust, Aberdeen

Abbreviations

ACD	acid citrate dextrose
ACTH	adrenocorticotrophic hormone
ADC	analogue-to-digital converter
AFTN	autonomously functioning nodules
ALRA	as low as reasonably achievable
ALI	annual limits on intake
ARDS	adult respiratory distress syndrome
AVM	arterio-venous malformation
BBB	blood brain barrier
BGO	bismuth germanate
CAD	coronary artery disease
CCK	cholecystokinin
CEA	Carcinoembryonic antigen
CFOV	central field of view
CGP	circulating granulocyte pool
CoR	centre of rotation
CoV	coefficient of variation
CPU	central processing unit
CRH	corticotropin releasing hormone
CSF	cerebrospinal fluid
CT	computed tomography
DMSA	2,3-dimercaptosuccinic acid
DSA	digital subtraction angiography
DTPA	diethylene triamine pentaacetic acid
DVT	deep vein thrombosis
EDE	effective dose equivalent
EPA	Environmental Protection Agency
ERPF	effective renal plasma flow
FDG	¹⁸ F-fluorodeoxyglucose
FoV	field of view
FWHM	full width at half maximum
FWTM	full width at tenth maximum
GFOV	geometrical field of view
GFR	glomerular filtration rate
GI	gastrointestinal
GMP	The Guide to Good Pharmaceutical Manufacturing Practice
HIDA	hepatic iminodiacetic acid
HIG	Human polyclonal immunoglobulin
HIPDM	N-trimethyl-N-(2-hydroxyl-3-methyl-5-iodobenzyl)-1,3-propanediamine
HM-PAO	hexamethylpropyleneamine oxime
HPLC	high performance liquid chromatography
HSA	human serum albumin
IBD	inflammatory bowel disease
IMP	N-isopropyl-[¹²⁵ I]-p-iodoamphetamine

ITLC	instant thin layer chromatography
IVC	inferior vena cava
IVU	intravenous urography
LAL	Limulus Amoebocyte Lysate
LDL	low density lipoprotein
LET	linear energy transfer
LLD	lower level energy discriminator
LOR	line of response
LSF	line spread function
LSO	lutetium oxyorthosilicate
MAA	human albumin macroaggregates
MAB	monoclonal antibodies
MAG3	benzoylmercaptoacetyl triglycerine
MCA	multichannel analyser
MDP	methylene diphosphonate
MGP	marginating granulocyte pool
MIBG	¹²³ I labelled meta-iodo-benzyl guanidine
MIBI	2-methoxy-isobutyl-isonitrile
MIRD	Medical Internal Radiation Dose Committee
MRI	magnetic resonance imaging
MTF	modulation transfer function
MTT	mean transit time
MUGA	multiple gated acquisition
NEC	noise equivalent counts
NP-59	¹³¹ I-6 β -iodomethyl-19-norcholesterol
OIH	orthoiodohippurate
PCP	pneumocystis carinii pneumonia
PE	pulmonary embolism
PET	positron emission tomography
PHA	pulse height analyser
PMT	photomultiplier tube
PPP	platelet-poor-plasma
PRP	platelet-rich-plasma
PTH	parathyroid hormone
PUO	pyrexia of unknown origin
PV	plasma volume
QA	quality assurance
RAIU	radioiodine thyroid uptake
RAM	random access memory
RBC	red blood cells
RBE	relative biological effectiveness
rCBF	regional cerebral bloodflow
RCP	radiochemical purity
RCV	red cell volume
ROI	region of interest
ROM	read only memory
RPA	radiation protection adviser
SD	standard deviation
SDAT	senile dementia of the Alzheimer type
SeHCAT	⁷⁵ Se-labelled tauroselcholic acid
SestaMIBI	2-methoxy-isobutyl-isonitrile
SPECT	single photon emission computed tomography
SUV	standardized uptake value
TAC	tiame activity curve
TBV	total blood volume

TLC	thin layer chromatography
TLD	thermoluminescent dosimetry
TRH	thyrotropin-releasing hormone
TSH	thyroid stimulating hormone
UTI	urinary tract infection

Contents

Chapter 1

Nuclear medicine imaging

Peter F Sharp	1
1.1 Introduction	1
1.2 The ideal radiopharmaceutical	1
1.3 The gamma camera	3
1.4 The potential of imaging with radiopharmaceuticals	12
1.5 References	12
1.6 Further reading	12

Chapter 2

Single-photon emission-computed tomography

Howard G Gemmell and Roger T Staff	13
2.1 Introduction	13
2.2 Theory of SPECT	13
2.3 Instrumentation	21
2.4 Quality issues	22
2.5 References	24

Chapter 3

Non-imaging radionuclide investigations

A T Elliott and T E Hilditch	25
3.1 Introduction	25
3.2 Instruments for the assay of radioactivity	25
3.3 Errors in measurement of radioactivity	27
3.4 Blood volume	29
3.5 ^{14}C -Urea breath test for helicobacter pylori (H. pylori)	31
3.6 Other breath tests	32
3.7 Red cell studies	32
3.8 GI blood and protein loss	33
3.9 Schilling test	34
3.10 Ferrokinetics	34
3.11 Renal studies	35
3.12 Thyroid uptake	36
3.13 Bile acid malabsorption	36

3.14	Radioimmunoassay	37
3.15	References	37
Chapter 4		
Data processing		
Gordon W Middleton		38
4.1	Introduction	38
4.2	The nuclear medicine computer system	38
4.3	Image acquisition techniques	40
4.4	Techniques for image presentation and processing	42
4.5	Conclusion	48
4.6	References	48
Chapter 5		
Quality assurance		
A T Elliott		49
5.1	Introduction	49
5.2	Gamma cameras	49
5.3	Emission tomography	62
5.4	Computer system	64
5.5	Dose calibrators	66
5.6	Automatic counters	67
5.7	Radiation monitors	67
5.8	Acceptance testing schedule	67
5.9	Routine quality control schedule	68
5.10	Implementation	69
5.11	References	70
Chapter 6		
The radiopharmacy		
James Doherty and David Graham		72
6.1	Introduction	72
6.2	Radiopharmacy design	72
6.3	Production of radiopharmaceuticals	76
6.4	Quality assurance of radiopharmaceuticals	88
6.5	Radiation protection in the radiopharmacy	97
6.6	Glossary of terms	98
6.7	References	98
Chapter 7		
Radiation protection		
P P Dendy, K E Godstone, and R W Barber		100
7.1	Introduction	100
7.2	Fundamentals of radiation biology	100

7.3	Dose limits for staff and patients	103
7.4	Design of facilities	106
7.5	Safety of staff	107
7.6	Safety of patients	110
7.7	Transport of radioactive materials	111
7.8	Disposal of waste	112
7.9	Legal requirements	114
7.10	Summary and conclusions	116
7.11	References	116
7.12	Further reading	117

Chapter 8

The central nervous system

Francis W Smith 118

8.1	Introduction	118
8.2	Anatomy and physiology	118
8.3	The conventional brain scan	119
8.4	Regional cerebral bloodflow imaging	134
8.5	Radionuclide cisternography	138
8.6	References	143
8.7	Further reading	143

Chapter 9

The cardiovascular system

S Walton 144

9.1	Anatomy and physiology	144
9.2	Acute infarction imaging	144
9.3	Radionuclide ventriculography	146
9.4	Myocardial perfusion imaging	153
9.5	Myocardial innervation	158
9.6	References	158

Chapter 10

The Lung

H W Gray 159

10.1	Introduction	159
10.2	Anatomy and physiology	159
10.3	Ventilation perfusion imaging	161
10.4	Diagnosis of venous thromboembolism	166
10.5	Diagnosis of alveolar disease	173
10.6	References	175
10.7	Further reading	175

Chapter 11**Gastrointestinal tract and liver**

L K Harding and A Notghi	176
11.1 Anatomy and physiology	176
11.2 Oesophageal motility	178
11.3 Gastro-oesophageal reflux	179
11.4 Milk scan	180
11.5 Gastric emptying	181
11.6 Small bowel transit	183
11.7 Colonic transit	183
11.8 Defaecography	186
11.9 Colloid liver scan	188
11.10 Scintigraph liver angiography	189
11.11 Splenic imaging	190
11.12 Hepatobiliary scintigraphy	190
11.13 Meckel's diverticulum	194
11.14 Inflammatory bowel disease	195
11.15 Tumour markers	196
11.16 Protein loss	198
11.17 Vitamin B ₁₂ absorption	199
11.18 SeHCAT	200
11.19 Breath tests	201
11.20 References	203

Chapter 12**Vascular and lymphatic systems**

Francis W Smith	204
12.1 Introduction	204
12.2 First-pass studies	204
12.3 Labelled red blood cell imaging	204
12.4 Venography	208
12.5 Deep venous thrombosis	209
12.6 Lymphoscintigraphy	210
12.7 References	212

Chapter 13**The urinary tract**

Francis W Smith and Howard G Gemmell	213
13.1 Introduction	213
13.2 Anatomy and physiology	213
13.3 Radiopharmaceuticals	214
13.4 The renogram	216
13.5 Renal clearance studies	219

13.6	Indications	219
13.7	Imaging methods	219
13.8	Clinical interpretation	220
13.9	The transplanted kidney	229
13.10	References	231

Chapter 14

The skeletal system

Francis W Smith	235
14.1 Introduction	235
14.2 Anatomy and physiology	235
14.3 Bone scan	235
14.4 Bone marrow scan	245
14.5 References	250
14.6 Suggested reading	252

Chapter 15

Thyroid, parathyroid, and adrenal gland imaging

W H Martin, M P Sandler, B Shapiro, and M D Gross	253
15.1 Introduction	253
15.2 The thyroid	253
15.3 The parathyroid glands	259
15.4 The adrenal glands	263
15.5 References	270

Chapter 16

Tumour imaging

A C Perkins	272
16.1 The clinical problem	272
16.2 Tumour physiology	273
16.3 Radiopharmaceuticals	273
16.4 Radionuclide bone imaging	274
16.5 [⁶⁷ Ga] gallium citrate	275
16.6 Radioiodine and thyroid carcinoma	277
16.7 <i>m</i> -iodobenzylguanidine	278
16.8 Radiolabelled monoclonal antibodies	279
16.9 Receptor mediated imaging	281
16.10 Intraoperative tumour localization	281
16.11 The role of nuclear medicine in the diagnostic process	283
16.12 References	284

*Chapter 17***Infection**

A M Peters	285
17.1 Introduction	285
17.2 Physiology of inflammation	285
17.3 White cell labelling techniques	287
17.4 Evaluation of labelled granulocyte function	293
17.5 Mechanism of ^{67}Ga uptake in inflammatory foci	293
17.6 Human polyclonal immunoglobulin (HIG)	293
17.7 Normal distribution and imaging protocol	296
17.8 Clinical applications	299
17.9 Approach to the patient with an undiagnosed fever	311
17.10 Alternative methods and future prospects	313
17.11 Acknowledgements	315
17.12 References	315

Chapter 18 **$^{99\text{m}}$ -technetium pertechnetate**

Francis W Smith	316
18.1 Introduction	316
18.2 Chemistry	316
18.3 Biodistribution	316
18.4 Stomach	317
18.5 Salivary glands	318
18.6 Thyroid	320
18.7 Choroid plexus	320
18.8 Small and large bowel	321
18.9 Kidney	321
18.10 Sweat glands	321
18.11 Testes	321
18.12 Lacrimal apparatus	322
18.13 Further reading	324

*Chapter 19***Positron emission tomography**

Peter F Sharp	325
19.1 Introduction	325
19.2 Principles of PET imaging	325
19.3 The PET imager	326
19.4 Performance of PET imagers	329
19.5 The gamma camera for PET imaging	331
19.6 Production of radiopharmaceuticals	332
19.7 Biological behaviour of radiopharmaceuticals	333
19.8 Clinical applications	335
19.9 References	338

Chapter 1

Nuclear medicine imaging

Peter F Sharp

1.1 Introduction

In nuclear medicine clinical information is derived from observing the distribution of a pharmaceutical administered to the patient. By incorporating a radionuclide into the pharmaceutical, measurements can be made of the distribution of this radiopharmaceutical by noting the amount of radioactivity present. These measurements may be carried out either *in vivo* or *in vitro*. *In vivo* imaging is the most common type of procedure in nuclear medicine, nearly all imaging being carried out with a gamma camera (see Section 1.3). It offers the potential, unique among imaging techniques, of demonstrating function rather than simply anatomy.

Where a knowledge of the precise amount of activity present in an organ is required and an image of the distribution is not essential, collimated scintillation probe detectors aligned with the organ of interest are used [1]

Table 1.1 Ideal characteristics of a radiopharmaceutical

Half-life should be similar to the length of the test
The radionuclide should emit gamma-rays and there should be no charged particle emissions
The energy of the gamma-rays should be between 50 and 300 keV
The radionuclide should be chemically suitable for incorporating into a pharmaceutical without altering its biological behavior
The radionuclide should be readily available at the hospital site
The pharmaceutical should localize only in the area of interest
The pharmaceutical should be eliminated from the body with a half-life similar to the duration of the examination
The radiopharmaceutical should be simple to prepare

or, in specialized centers, the technique of positron emission tomography may be available (see Chapter 19). If the amount of radioactivity present is very low then high-sensitivity whole-body counters, consisting of heavily shielded probe detectors, are necessary [2].

In vitro measurements are made on samples of material taken from the patient, such as breath, urine, and faeces, to determine the amount of radiopharmaceutical present. Such measurements are made using gamma- or beta-sample counting techniques (see Chapter 3).

The diagnostic information is provided by the action of the pharmaceutical, and the role of the radioactivity is purely a passive one enabling the radiopharmaceutical to be localized. For this reason it is possible to use low levels of radioactivity and so the potential hazard to the patient can be kept small (see Chapter 7).

1.2 The ideal radiopharmaceutical

The specific features looked for in the ideal radiopharmaceutical are summarized in Table 1.1. It must be emphasized, however, that no single radiopharmaceutical actually has all these properties. As the radionuclide label and the pharmaceutical perform different functions, the particular features regarded as desirable for them can largely be considered separately.

1.2.1 Radionuclides

Half-life

The half-life of the radionuclide determines how quickly the radioactivity will decay. Obviously, if the half-life is very short then the activity will have decayed to a very low level before imaging has started. On the other hand, if it is too long then the patient will remain radioactive for a considerable time, and in order to reduce the possibility of radiation damage the amount of activity

administered will have to be kept low. Roughly, the half-life should be of a similar length to that of the examination, usually a few hours.

Type and energy of emission

For imaging it is first necessary that the radiation given off should be sufficiently penetrating to allow it to be detected externally even though it may need to pass through several centimetres of tissue. This limits the choice to gamma- or X-rays. The energy of the radiation will also affect its ability to penetrate tissue: the higher the energy the better it will be. However, the higher the energy the more difficult it will be to stop the gamma-ray in the detector of the imaging device. In practice gamma-rays with energies between 50 keV and 300 keV are preferred, about 150 keV being ideal.

The radiation dose received by the patient must also be considered. It is necessary to avoid those radionuclides which have significant particulate (i.e. alpha and beta) emissions, which owing to their short range will simply increase radiation dose without contributing to the image quality. As the purpose of radioactive decay is to redress an imbalance in the ratio of protons to neutrons in the nucleus, it is clear that simple gamma-decay will be accompanied by the emission of a charged particle, usually a beta-ray. There are, however, two decay processes which avoid this problem: isomeric transition and electron capture. Particles will still be emitted, namely Auger and conversion electrons, but at a considerably lower rate than the one per gamma experienced with other modes of decay.

Pharmaceutical labelling

While the prime consideration in choosing a radionuclide is that its manner of decay should be suitable for *in vivo* imaging, it must not be forgotten that this material must be incorporated into a pharmaceutical. Unfortunately all the elements of biological interest, such as carbon, nitrogen, and oxygen, do not have radioisotopes meeting the criteria of Table 1.1. These particular elements do, however, have radioisotopes which emit positrons. These positively charged electrons annihilate with an electron to produce a pair of 511-keV gamma-rays. While the energy of these gamma-rays is such that the sensitivity of detection in the crystal of a standard gamma camera will be low, nevertheless several cameras have been adapted for positron imaging either by fitting them with a high-energy collimator or by using coincidence electronics. The most effective way of imaging positron-emitting radiopharmaceuticals is still with specialized equipment (see Chapter 19).

Despite the potential problems, pharmacists and radiochemists have been very successful in incorporating some of the most unlikely material, such as the

widely used radioisotope of technetium, into a large range of pharmaceuticals. This problem will be considered in Chapter 6.

Production of radionuclides

Radionuclides can be produced from three sources: the nuclear reactor, the cyclotron, or a generator. It is not intended to go into detail about the process of production of radioactive material and the interested reader is recommended to read references [3] and [4].

The reactor radionuclides are produced either by introducing a target of stable material into the neutron flux found inside the reactor, or by separating out fission products from the fuel rods or a uranium target. As neutron irradiation increases the number of neutrons relative to the number of protons in the nucleus it will produce radionuclides which decay predominantly by beta-decay.

The cyclotron produces a beam of charged particles, such as alphas and deuterons, which can be aimed at the target. The resulting radionuclide will have an excess of charge and so will decay either by emission of a positively charged particle (a positron) or by the capture of a negative charge (electron capture). The latter, as has been mentioned earlier, is a particularly useful decay process as it has a gamma-to-beta ratio greater than unity.

Obviously in most instances radionuclides produced by these two routes will be shipped to the hospital from a central manufacturing site. This creates a problem, since short-lived radionuclides will decay significantly during transportation. Fortunately the third mode of production, the generator, provides an answer, at least for certain radionuclides. The generator will be discussed in Chapter 6 but basically it depends upon the existence of a long-lived radionuclide which decays into the required short-lived radionuclide. All that is then needed is for this long-lived parent to be supplied in the form of a generator from which the short-lived daughter can be chemically extracted when required. This generator is the source of the radionuclide most commonly used in nuclear medicine, technetium-99m, the parent material in this case being molybdenum-99.

A list of commonly used radionuclides is given in Table 1.2 together with their mode of production and characteristics of decay.

Selection of pharmaceutical

The most important feature required of the pharmaceutical is that it should be taken up rapidly and completely in the biological system of interest. In practice most radiopharmaceuticals also localize in other parts of the body, and if these are radiosensitive the amount of activity which can be administered will be limited (see Chapter